KEY FINDINGS The Europe Continuous Glucose Monitoring System (CGMS) market is expected to rise from $255.1 million in 2017 to $3412 million by 2026, exhibiting a CAGR of 33.40% over the forecast period of 2018-2026. And, the Europe Self-Monitoring of Blood Glucose (SMBG) market is expected to rise from $3005.1 million in 2017 to $5873.9 million by 2026, at a CAGR of 7.94% over the forecasted period.
MARKET INSIGHTS The number of diabetic patients in this region have increased tremendously over the past few years. This, in turn, increased the need for awareness amongst the people about the advanced CGM devices to monitor glucose levels and manage insulin delivery. Also, there was a need for improvement of health infrastructure for the same. Each of the 28 countries in Europe has its own system for approval of distributing and supplying medical devices. The U.K market dominated the European scene in 2017. However, the French market is expected to rise with the highest CAGR over the forecast period. This is due to the French's health infrastructure and services being one of the best in the world.
COMPETITIVE INSIGHTS Companies like Beurer GmbH, Abbott, Medtronic, Dexcom, Animas, Sanofi, Pfizer, GlaxoSmithKline, and AstraZeneca are leading in this region.[by Global Information]